Zofia R.
- Country
- Poland
- Department
- NA
Research Overview
- Efficacy and Safety Evaluation of Deucravacitinib in Biologic-Naïve Patients with Active Psoriatic Arthritis: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of the Efficacy and Safety of GLPG3667 in Adults with Active Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Study
- A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Data & Insights
Has run more than one trial at 19 of 152 partner sites.
Specializations
Autoimmune Disorders
This investigator specializes in the treatment of Systemic Lupus Erythematosus (SLE), conducting research into novel therapeutic approaches for managing this complex autoimmune condition. Their work encompasses long-term safety evaluations and efficacy assessments of innovative treatments for SLE patients.
- SLE Management
- Autoimmune Disease Therapeutics
- Long-term Treatment Outcomes
Neurological Conditions
The investigator focuses on treating chronic neuropathic pain conditions, particularly in cases of postherpetic neuralgia and peripheral nerve injury. Their research explores innovative therapeutic interventions for managing moderate to severe chronic pain syndromes.
- Neuropathic Pain Management
- Pain Intensity Assessment
- Neuralgia Treatment
Rheumatological Disorders
Research interests include the treatment of Psoriatic Arthritis (PsA), with particular emphasis on developing therapeutic strategies for patients who have not previously received biological disease-modifying treatments. The investigator evaluates novel approaches for managing active PsA.
- Psoriatic Arthritis Treatment
- Rheumatic Disease Management
- Novel Therapeutic Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.